secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2022-10-20T23:59:59+00:00
Accession:  0001104659-22-110103
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HOOKIPA signs collaboration with Roche for KRAS-mutated cancer therapy; $25M upfront, up to $930M milestones
--------------------------------------------------------------------------------

- HOOKIPA receives $25 million upfront; eligible for up to ~$930 million in total milestone payments plus tiered royalties.
- Roche licenses HB-700, an arenaviral immunotherapy for KRAS-mutated cancers; HOOKIPA conducts research through Phase 1b.
- Roche obtains an exclusive option to license a second undisclosed arenaviral immunotherapy for an additional $15 million payment.
- Tiered royalties of high single-digit to mid-teens percent on worldwide net sales for both programs upon commercialization.
- First oncology licensing collaboration for HOOKIPA; partnership validates its arenavirus platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000110465922110103/0001104659-22-110103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000110465922110103/tm2228531d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-110103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer